drugset / Trial / NCT00002589

Lymphocyte Therapy in Treating Patients With Kidney Cancer

NCT00002589

Phase 2 Unknown 90 enrolled National Cancer Institute (NCI)
Treatment

Summary

RATIONALE: Treating a person's lymphocytes with interleukin-2 and monoclonal antibody may help them kill more cancer cells when they are put back in the body. PURPOSE: This phase II trial is studying how well lymphocyte therapy works in treating patients with stage III or stage IV kidney cancer.

Timeline

Start
1994-07
Primary completion
Completion

Drugs

EvaluationDrugModalityDoseRoute
Subject therapeutic autologous lymphocytes Cell therapy
Background aldesleukin Protein / enzyme biologic
Background muromonab-CD3 Monoclonal antibody

Indications